1. Circulating suPAR in two cohorts of primary FSGS
- Author
-
Dieter Haffner, Karsten M. Heil, Ali Anarat, Aaron L. Friedman, Fatih Ozaltin, Howard Trachtman, Frederick J. Kaskel, Chuanhui Dong, Gian M. Ghiggeri, Agnes Trautmann, June L. McMahan, Milena Radeva, Dagmar-Christiane Fischer, Debbie S. Gipson, Jing Li, Sevinç Emre, Changli Wei, Jennifer J. Gassman, Franz Schaefer, Jochen Reiser, Çocuk Sağlığı ve Hastalıkları, and Çukurova Üniversitesi
- Subjects
Male ,medicine.medical_specialty ,Adolescent ,Renal function ,urologic and male genital diseases ,Gastroenterology ,Receptors, Urokinase Plasminogen Activator ,Cohort Studies ,Young Adult ,Internal medicine ,medicine ,Humans ,Child ,Randomized Controlled Trials as Topic ,Proteinuria ,business.industry ,Glomerulosclerosis, Focal Segmental ,Glomerulosclerosis ,General Medicine ,Urology & Nephrology ,Mycophenolic Acid ,medicine.disease ,Urokinase receptor ,C-Reactive Protein ,SuPAR ,Nephrology ,Child, Preschool ,Immunology ,Cohort ,Female ,medicine.symptom ,business ,Nephrotic syndrome ,Immunosuppressive Agents ,Cohort study - Abstract
PubMedID: 23138488 Overexpression of soluble urokinase receptor (suPAR) causes pathology in animal models similar to primary FSGS, and one recent study demonstrated elevated levels of serum suPAR in patients with the disease. Here, we analyzed circulating suPAR levels in two cohorts of children and adults with biopsy-proven primary FSGS: 70 patients from the North America-based FSGS clinical trial (CT) and 94 patients from PodoNet, the Europe-based consortium studying steroid-resistant nephrotic syndrome. Circulating suPAR levels were elevated in 84.3% and 55.3% of patients with FSGS patients in the CT and PodoNet cohorts, respectively, compared with 6% of controls (P
- Published
- 2012